


HAYAN AL MALULI, MD

 Department of Medicine,
Temple University Hospital,
Philadelphia, PA

ARNOLD B. MESHKOV, MD, MBA, FACC

 Professor of Clinical Medicine, Temple
University School of Medicine, Philadelphia, PA

A short story of the short QT syndrome

ABSTRACT

Short QT syndrome is a recently recognized cause of cardiac rhythm disorders, including sudden cardiac death. Although the syndrome is rare, its potential lethality justifies routinely screening the electrocardiograms of patients with syncope or unexplained atrial or ventricular arrhythmias to look for this diagnosis. This review discusses recent advances in the understanding of the pathogenesis of this syndrome and outlines some of the challenges in establishing the diagnosis.

KEY POINTS

Short QT syndrome is a genetic disease described initially in young patients who had atrial fibrillation or who died suddenly with no apparent structural heart disease.

The diagnosis is established by the finding of a short QT interval. However, other factors including personal and family history are also important in establishing the diagnosis.

The current recommendations for managing patients with short QT syndrome are not evidence-based. We encourage consultation with centers that have special interest in QT-interval-related disorders.

Placement of an implantable cardioverter-defibrillator is considered the standard of care, especially in survivors of sudden cardiac death, ventricular fibrillation, or ventricular tachycardia. Unfortunately, a higher incidence of inappropriate shocks adds to the challenges of managing this potentially deadly disease.

SUDDEN CARDIAC DEATH in a young person is a devastating event that has puzzled physicians for decades. In recent years, many of the underlying cardiac pathologies have been identified. These include structural abnormalities such as hypertrophic cardiomyopathy and nonstructural disorders associated with unstable rhythms that lead to sudden cardiac death.

The best known of these “channelopathies” are the long QT syndromes, which result from abnormal potassium and sodium channels in myocytes. Recently, interest has been growing in a disorder that may carry a similarly grim prognosis but that has an opposite finding on electrocardiography (ECG).

Short QT syndrome is a recently described heterogeneous genetic channelopathy that causes both atrial and ventricular arrhythmias and that has been documented to cause sudden cardiac death.

In 1996, a 37-year-old woman from Spain died suddenly; ECG several days earlier had shown a short QT interval of 266 ms.¹ Two years later, an unrelated 17-year-old American woman undergoing laparoscopic cholecystectomy suddenly developed atrial fibrillation with a rapid ventricular response.¹ Her QT interval was 225 ms. Her brother had a QT interval of 240 ms, and her mother’s was 230 ms. The patient’s maternal grandfather had a history of atrial fibrillation, and his QT interval was 245 ms. These cases led to the description of this new clinical syndrome (see below).²

CLINICAL FEATURES

Short QT syndrome has been associated with both atrial and ventricular arrhythmias. Atrial fibrillation, polymorphic ventricular



FIGURE 1. An electrocardiogram of a patient with short QT syndrome shows sinus rhythm and a rate of about 80 bpm. Note the QT interval of about 280 ms and the corrected QT interval of about 320 ms. Also note the tall and peaked T waves, especially in leads V₂ to V₄ (arrows). These T waves might be interpreted as R waves by an implantable cardioverter-defibrillator and therefore provoke inappropriate shocks from the device (see text for details). (Paper speed 25 mm/sec; each 1 mm represents 0.04 seconds.)

REPRODUCED FROM MORENO-REVIRIEGO S, MERINO JL. SHORT QT SYNDROME. E-JOURNAL OF THE EUROPEAN SOCIETY OF CARDIOLOGY COUNCIL FOR CARDIOLOGY PRACTICE 2010; 9, WITH PERMISSION FROM THE EUROPEAN SOCIETY OF CARDIOLOGY. [HTTP://WWW.ESCARDIO.ORG/COMMUNITIES/COUNCILS/CCP/E-JOURNAL/VOLUME9/PAGES/SHORT_QT_SYNDROME_REVIRIEGO.ASPX#.UFIL-O1M518](http://www.escardio.org/communities/councils/ccp/e-journal/volume9/pages/short_qt_syndrome_reviriego.aspx#.UFIL-O1M518). ACCESSED OCTOBER 23, 2012.

Short QT syndrome causes atrial and ventricular arrhythmias and sudden cardiac death

tachycardia, and ventricular fibrillation have all been well described. Patients who have symptoms usually present with palpitations, presyncope, syncope, or sudden or aborted cardiac death.^{3,4}

ELECTROCARDIOGRAPHIC FEATURES

The primary finding on ECG is a short QT interval. However, others have been noted (FIGURE 1):

Short or absent ST segment

This finding is not merely a consequence of the short QT interval. In 10 patients with short QT syndrome, the distance from the J point to the peak T wave ranged from 80 to 120 ms. In 12 healthy people whose QT interval was less than 320 ms, this distance ranged from 150 ms to 240 ms.⁵

Tall and peaked T wave

A tall and peaked T wave is a common feature in short QT syndrome. However, it was also evident in people with short QT intervals who had no other features of the syndrome.⁵

QT response to heart rate

Normally, the QT interval is inversely related to the heart rate, but this is not true in short QT syndrome: the QT interval remains relatively fixed with changes in heart rate.^{6,7} This feature is less helpful in the office setting but may be found with Holter monitoring by measuring the QT interval at different heart rates.

BUT WHAT IS CONSIDERED A SHORT QT INTERVAL?

In clinical practice, the QT interval is corrected for the heart rate by the Bazett formula:

$$\text{Corrected QT (QTc)} = \frac{\text{QT interval}}{\text{square root of the RR interval}}$$

Review of ECGs from large populations in Finland (n = 10,822), Japan (n = 12,149), the United States (n = 79,743), and Switzerland (n = 41,676) revealed that a QTc value of 350 ms in males and 365 ms in females was 2.0 standard deviations (SD) below the mean.⁸⁻¹¹ However, a QTc less than the 2.0 SD cutoff did not necessarily equal arrhythmogenic poten-

tial. This was illustrated in a 29-year follow-up study of Finnish patients with QTc values as short as 320 ms, in whom no arrhythmias were documented.⁸ Conversely, some patients with purported short QT syndrome had QTc intervals as long as 381 ms.¹²

Similar problems with uncertainty of values have plagued the diagnosis of long QT syndrome.¹³ The lack of reference ranges and the overlap between healthy and affected people called for the development of a scoring system that involves criteria based on ECG and on the clinical evaluation.^{14,15}

■ ESTABLISHING THE DIAGNOSIS OF SHORT QT SYNDROME

Clearly, the diagnosis of short QT syndrome can be challenging to establish. The first step is to rule out other causes of a short QT interval.

Differential diagnosis of short QT interval

In addition to genetic channelopathies, other causes of short QT interval must be ruled out before entertaining the diagnosis of short QT syndrome.

- **Hypercalcemia** is the most important of these: there is usually an accompanying prolonged PR interval and a wide QRS complex¹⁶
- **Hyperkalemia**¹⁷
- **Acidosis**¹⁷
- **Increased vagal tone**¹⁷
- **After ventricular fibrillation** (thought to be related to increased intracellular calcium)¹⁸
- **Digitalis use**¹⁹
- **Androgen use**.²⁰

Interestingly, a shorter-than-expected QT interval was noted in patients with chronic fatigue syndrome.²¹

Which interval to use: QT or QTc?

Unfortunately, most population-based studies that searched for a short QT interval on ECG have used QTc as the main search parameter.⁸⁻¹¹ As already mentioned, in patients with short QT syndrome, the QT interval is, uniquely, not shortened if the heart beats faster. In contrast, the QTc often overestimates the QT interval in patients with short QT syndrome, especially when the heart rate is in the 80s to 90s.¹⁶

TABLE 1

Diagnostic criteria for short QT syndrome

CRITERIA	POINTS
Corrected QT interval^a	
< 370 ms	1
< 350 ms	2
< 330 ms	3
Interval from J point to T peak < 120 ms^{a,b}	1
Clinical history^c	
History of sudden cardiac arrest	2
Documented polymorphic ventricular tachycardia or ventricular fibrillation	2
Unexplained syncope	1
Atrial fibrillation	1
Family history^d	
First- or second-degree relative with high probability of short QT syndrome	2
First- or second-degree relative with autopsy-negative sudden cardiac death	1
Sudden infant death syndrome	1
Genotype	
Genotype-positive	2
Mutation of undetermined significance in a culprit gene	1
TOTAL	—
Probability of short QT syndrome	
High	4 points
Intermediate	3 points
Low	2 points

^aElectrocardiogram must be recorded in the absence of modifiers known to shorten the QT interval. A minimum of 1 point must be obtained in the electrocardiographic sections in order to obtain additional points.

^bThe interval from the J point to the T wave peak must be measured in the precordial lead with the T wave of greatest amplitude.

^cClinical history events must occur in the absence of an identifiable cause, including structural heart disease. In the following group of events, points can be received for only one: cardiac arrest, documented polymorphic ventricular tachycardia, or unexplained syncope.

^dFamily history points can only be received once in this section.

REPRINTED FROM GOLLOB MH, REDPATH CJ, ROBERTS JD. THE SHORT QT SYNDROME: PROPOSED DIAGNOSTIC CRITERIA. J AM COLL CARDIOL 2011; 57:802-812, WITH PERMISSION FROM ELSEVIER.

In a review of cases of short QT syndrome worldwide, Bjerregaard et al²² found that the QT interval ranged from 210 ms to 340 ms with a mean \pm 2 SD of 282 ± 62 ms. On the other hand, the QTc ranged from 248 ms to 345 ms with a mean \pm 2 SD of 305 ± 42 ms.

Therefore, correction formulas (such as the

In short QT syndrome, the QT interval is not affected by the heart rate

Bazett formula) do not perform well in ruling in the diagnosis of short QT syndrome—and they do even worse in ruling it out.^{16,22}

To establish a diagnosis of short QT syndrome in someone with prior evidence of atrial or ventricular fibrillation, a QT interval less than 340 ms or a QTc less than 345 ms is usually sufficient.²² In borderline cases in which the QT interval is slightly longer, some experts recommend other tests, although strong evidence validating their predictive value does not exist. These tests include genotyping, analysis of T wave morphology, and electrophysiologic studies.¹⁶

Recently, Gollob et al²³ proposed a scoring system for short QT syndrome (TABLE 1). After reviewing the literature and comparing the diagnostic markers, the investigators determined diagnostic criteria that, when applied to the previously reported cases, were able to identify 58 (95.08%) of 61 patients with short QT syndrome (ie, a sensitivity of 95%).

For patients with intermediate probability, the authors recommended continued medical and ECG surveillance as well as ECGs for first-degree relatives, to further clarify the diagnosis.

Again, a principal caveat about this system is that it relies on the QTc interval rather than the QT interval to diagnose short QT syndrome.

■ THE SCOPE OF THE DISEASE

In a recent review of the literature, Gollob et al²³ found a total of 61 cases of short QT syndrome reported in English. The cohort was predominantly male (75.4%), and most of the symptomatic patients presented during late adolescence and early adulthood. However, there have been reports of infants (4 and 8 months old), and of a man who presented for the first time at the age of 70. Of note, the authors only considered short QT syndrome types 1, 2, and 3 (see below) in their search for cases.

Whether the syndrome is truly this rare or, rather, whether many physicians are not aware of it is still to be determined. In addition, it is possible that incorrectly measuring the QT interval contributes to the lack of identification of this entity. Both of these factors were implicated in the rarity of reported long QT syndrome early after its discovery.^{14,15}

■ MUTATIONS IN CARDIAC ION CHANNELS

Five distinct genetic defects have been associated with short QT syndrome. As in long QT syndrome, these give rise to subtypes of short QT syndrome, which are numbered 1 to 5 (see below).

The cardiac action potential

To understand how the mutations shorten the QT interval, we will briefly review of the cardiac myocyte action potential.²⁴ In nonpace-maker cells of the heart, the activation of the cell membrane initiates a series of changes in ion channels that allow the movement of ions along an electrical gradient. This movement occurs in five phases and is repeated with every cardiac cycle (FIGURE 2).

In phase 0, the cardiac cell rapidly depolarizes.

Repolarization occurs in phases 1, 2, and 3 and is largely a function of potassium ions leaving the cell. During phase 2, calcium and sodium ions enter the cell and balance the outward potassium flow, creating the “flat” portion of the repolarization curve. Phase 3 is the main phase of repolarization in which the membrane potential rapidly falls back to its resting state (−90 mV). During phases 1 and 2, the cell membrane is completely refractory to stimulation, whereas phase 3 is divided into three parts:

- The effective refractory period: the cell is able to generate a potential that is too weak to be propagated
- The relative refractory period: the cell can respond to a stimulus that is stronger than normal
- The supernormal phase: the last small portion of phase 3, in which a less-than-normal stimulus can yield a response in the cell.

In phase 4, the cell is completely repolarized, and the cycle can start again.

Five types of short QT syndrome

Short QT syndrome 1. In 2004, Brugada et al²⁵ identified the first mutation that causes abnormal shortening of the action potential duration. In contrast to the mutations that underlie long QT syndrome, this mutation actually causes a gain of function in the gene

Normal cardiac cycle


Phase 0. The cell quickly depolarizes as sodium rapidly moves into the cell via the I_{Na} channel

Phase 1. The cell rapidly partially repolarizes as potassium leaves the cell via the I_{to} channel

Phase 2. Repolarization reaches a plateau, with sodium continuing to enter the cell via a slow I_{Na+} channel along with calcium via L-type I_{Ca} channels, balanced by outward movement of potassium (the rapid-acting current I_{Kr} , and later the slow-acting current I_{Ks}).

Phase 3. The cell repolarizes further, as the outward currents (I_{Kr} , I_{Ks}) and the inward-rectifier, I_{K1} increase.

Phase 4. The cell is completely repolarized and ready to repeat the cycle.



Short QT syndrome. The action potential is shortened in short QT syndrome. This is usually at the expense of the refractory period (Thick arrows indicate enhanced currents due to gain-of-function mutations.) See text for details.

FIGURE 2. Short QT syndrome is caused by gain-of-function mutations in cardiac potassium channels.

ADAPTED FROM MORENO-REVIRIEGO S, MERINO JL. SHORT QT SYNDROME. E-JOURNAL OF THE EUROPEAN SOCIETY OF CARDIOLOGY COUNCIL FOR CARDIOLOGY PRACTICE 2010; 9, WITH PERMISSION FROM THE EUROPEAN SOCIETY OF CARDIOLOGY. [HTTP://WWW.ESCARDIO.ORG/COMMUNITIES/COUNCILS/CCP/E-JOURNAL/VOLUME9/PAGES/SHORT_QT_SYNDROME_REVIRIEGO.ASPX#.UFIL-Q1MS18](http://www.escardio.org/communities/councils/ccp/e-journal/volume9/pages/short_qt_syndrome_reviriego.aspx#.UFIL-Q1MS18). ACCESSED OCTOBER 23, 2012.

coding the rapidly acting delayed potassium current (I_{Kr}) channel proteins *KCNH2* or *HERG*. Potassium leaving at a more rapid rate causes the cell to repolarize more quickly and shortens the QT interval. The clinical syndrome associated with *KCNH2* gene gain-

of-function mutation is called short QT syndrome 1.

Short QT syndromes 2 and 3. Other IK (potassium channel) proteins have been implicated as well. Gain-of-function mutations in the *KCNQ1* and *KCNJ2* genes are

believed to account for short QT syndromes 2 and 3, respectively. *KCNQ1* codes for the IKs protein, and *KCNJ2* codes for the IK1 protein.^{26,27}

Short QT syndromes 4 and 5 were identified by Antzelevitch et al,²⁸ who described several patients who had a combination of channel abnormalities and ECG findings. Their ECGs showed “Brugada-syndrome-like” ST elevation in the right precordial leads, but with a short QT interval. These new syndromes were found to be associated with genetic abnormalities distinct from those of Brugada syndrome and other short QT syndromes. These abnormalities involved loss-of-function mutations in the *CACNA1C* gene (which codes for the alpha-1 subunit of the L-type cardiac calcium channel) and in the *CACNB2* gene (which codes for the beta-2b subunit of the same channel). The two defects correspond to the clinical syndromes short QT syndrome 4 and short QT syndrome 5, respectively.²⁸

MECHANISM OF ARRHYTHMOGENESIS IN SHORT QT SYNDROME

The myocardium is made of different layers: the epicardium, the endocardium, and the middle layer of myocytes composed mainly of M cells. Cells in the different layers differ in the concentration of their channels and can be affected differently in various syndromes. When cells in one or two of the layers repolarize at a rate different from cells in another layer, they create different degrees of refractoriness, which establishes the potential for reentry circuits to form.

It is believed that in short QT syndrome the endocardial cells and M cells repolarize faster than the epicardial cells, predisposing to reentry and arrhythmias. This accentuation of “transmural dispersion of repolarization” accounts for arrhythmogenesis in short QT syndrome as well as in long QT syndrome and the Brugada syndromes. The difference between these syndromes appears to be the layer or area of the myocardium that is affected more by the channelopathy (the M cells in long QT syndrome and the epicardium of the right ventricle in the Brugada syndrome).²⁹

WHEN TO THINK OF SHORT QT SYNDROME

In any survivor of sudden cardiac death, the QT interval should be thoroughly scrutinized, and family members should undergo ECG. Patients in whom a short QT interval is incidentally discovered and for which other reasons are ruled out (see differential diagnosis) should be encouraged to have family members undergo ECG. Other potential patients are young people who develop atrial fibrillation and patients who have idiopathic ventricular fibrillation.⁴

TREATMENT AND PROGNOSIS

Evidence-based recommendations for the management of short QT syndrome do not yet exist, mainly because the number of patients identified to date is small.

Implantable cardioverter-defibrillators

Although placing an implantable cardioverter-defibrillator (ICD) seems to be warranted in patients who experience ventricular fibrillation, ventricular tachycardia, or aborted cardiac death, or in patients who have a family history of the same symptoms, the best management option is less clear for patients who have no symptoms and no family history.³⁰ In addition, some patients may not want an ICD or may even not qualify for this therapy.

A unique problem with ICDs in short QT syndrome stems from one of the syndrome’s main features on ECG: the tall and peaked T wave that closely follows the R wave can sometimes be interpreted as a short R-R interval, provoking an inappropriate shock from the ICD.³¹

For the above reasons, we strongly encourage consulting a center with expertise in QT-interval-related disorders before placing an ICD in a patient suspected of having short QT syndrome.

Antiarrhythmic drugs

Prolongation of the QT interval (and the effective refractory period) with drugs has been an interesting area of research. Gaita et al³² studied the effect of four antiarrhythmics—flecainide (Tambocor), sotalolol (Betapace), ibutilide (Corvert), and quinidine—in six patients

In any survivor of sudden cardiac death, the QT interval should be thoroughly scrutinized, and family members should undergo ECG

with short QT syndrome. Only quinidine was associated with significant QT prolongation, from 263 ± 12 ms to 362 ± 25 ms. This resulted in a longer ventricular effective refractory period (> 200 ms), and ventricular fibrillation was no longer inducible during provocative testing.

In a recent study of long-term outcomes of 53 patients with short QT syndrome, Giustetto et al³³ noticed that none of the patients taking quinidine, including those with a history of cardiac arrest, had any further arrhythmic events. On the other hand, the incidence of arrhythmic events during the follow-up was 4.9% per year in patients not taking this drug.

Quinidine had a stronger effect on the QT interval in patients with the *HERG* mutation than in those without.

RESEARCH MAY LEAD TO A BETTER UNDERSTANDING OF OTHER DISEASES

The short QT syndrome is one of the most recently recognized cardiac channelopathies associated with malignant arrhythmias. As with long QT syndrome, research in short QT syndrome may lead to a better understanding of the pathogenesis of more common but still poorly understood arrhythmias such as lone atrial fibrillation and idiopathic ventricular fibrillation. ■

REFERENCES

1. The Short QT Syndrome http://www.shortqtsyndrome.org/short_qt_history.htm. Accessed October 30, 2012.
2. Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? *Cardiology* 2000; 94:99–102.
3. Giustetto C, Di Monte F, Wolpert C, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. *Eur Heart J* 2006; 27:2440–2447.
4. Viskin S, Zeltser D, Ish-Shalom M, et al. Is idiopathic ventricular fibrillation a short QT syndrome? Comparison of QT intervals of patients with idiopathic ventricular fibrillation and healthy controls. *Heart Rhythm* 2004; 1:587–591.
5. Anttonen O, Junttila MJ, Maury P, et al. Differences in twelve-lead electrocardiogram between symptomatic and asymptomatic subjects with short QT interval. *Heart Rhythm* 2009; 6:267–271.
6. Redpath CJ, Green MS, Birnie DH, Gollob MH. Rapid genetic testing facilitating the diagnosis of short QT syndrome. *Can J Cardiol* 2009; 25:e133–e135.
7. Wolpert C, Schimpf R, Giustetto C, et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in *HERG*. *J Cardiovasc Electrophysiol* 2005; 16:54–58.
8. Anttonen O, Junttila MJ, Rissanen H, Reunanen A, Viitasalo M, Hui-kuri HV. Prevalence and prognostic significance of short QT interval in a middle-aged Finnish population. *Circulation* 2007; 116:714–720.
9. Funada A, Hayashi K, Ino H, et al. Assessment of QT intervals and prevalence of short QT syndrome in Japan. *Clin Cardiol* 2008; 31:270–274.
10. Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. *J Electrocardiol* 2007; 40:228–234.
11. Kobza R, Roos M, Niggli B, et al. Prevalence of long and short QT in a young population of 41,767 predominantly male Swiss conscripts. *Heart Rhythm* 2009; 6:652–657.
12. Itoh H, Sakaguchi T, Ashihara T, et al. A novel *KCNH2* mutation as a modifier for short QT interval. *Int J Cardiol* 2009; 137:83–85.
13. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. *N Engl J Med* 1992; 327:846–852.
14. Schwartz PJ. Idiopathic long QT syndrome: progress and questions. *Am Heart J* 1985; 109:399–411.
15. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. *Circulation* 1993; 88:782–784.
16. Bjerregaard P, Nallapaneni H, Gussak I. Short QT interval in clinical practice. *J Electrocardiol* 2010; 43:390–395.
17. Maury P, Extramiana F, Sbragia P, et al. Short QT syndrome. Update on a recent entity. *Arch Cardiovasc Dis* 2008; 101:779–786.
18. Kontny F, Dale J. Self-terminating idiopathic ventricular fibrillation presenting as syncope: a 40-year follow-up report. *J Intern Med* 1990; 227:211–213.
19. Cheng TO. Digitalis administration: an underappreciated but common cause of short QT interval. *Circulation* 2004; 109:e152.
20. Hancox JC, Choisy SC, James AF. Short QT interval linked to androgen misuse: wider significance and possible basis. *Ann Noninvasive Electrocardiol* 2009; 14:311–312.
21. Naschitz J, Fields M, Isseroff H, Sharif D, Sabo E, Rosner I. Shortened QT interval: a distinctive feature of the dysautonomia of chronic fatigue syndrome. *J Electrocardiol* 2006; 39:389–394.
22. Bjerregaard P, Collier JL, Gussak I. Upper limits of QT/QTc intervals in the short QT syndrome. Review of the world-wide short QT syndrome population and 3 new USA families. *Heart Rhythm* 2008; 5:AB43.
23. Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnostic criteria. *J Am Coll Cardiol* 2011; 57:802–812.
24. Shih HT. Anatomy of the action potential in the heart. *Tex Heart Inst J* 1994; 21:30–41.
25. Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in *HERG*. *Circulation* 2004; 109:30–35.
26. Bellocq C, van Ginneken AC, Bezzina CR, et al. Mutation in the *KCNQ1* gene leading to the short QT-interval syndrome. *Circulation* 2004; 109:2394–2397.
27. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the *KCNJ2* gene. *Circ Res* 2005; 96:800–807.
28. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. *Circulation* 2007; 115:442–449.
29. Antzelevitch C. Heterogeneity and cardiac arrhythmias: an overview. *Heart Rhythm* 2007; 4:964–972.
30. Lunati M, Bongiorni MG, Boriani G, et al. *Linee guida AIAC 2006 all'impianto di pacemaker, dispositivi per la resincronizzazione cardiaca (CRT) e defibrillatori automatici impiantabili (ICD)*. *GIAC* 2005; 8:1–58.
31. Schimpf R, Wolpert C, Bianchi F, et al. Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. *J Cardiovasc Electrophysiol* 2003; 14:1273–1277.
32. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. *J Am Coll Cardiol* 2004; 43:1494–1499.
33. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. *J Am Coll Cardiol* 2011; 58:587–595.

ADDRESS: Hayan Al Maluli, MD, Internal Medicine Residency Program, Department of Medicine, Temple University Hospital, 812 Parkinson Pavilion, 3401 North Broad Street, Philadelphia, PA 19140; e-mail: hayan.almaluli@tuhs.temple.edu.